Kheng Joe Lau, MD
Endocrinology, Diabetes & Metabolism · Baldwin, WINPI 1144673856
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 60.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $2,591, more than ten times the $48 reported in 2022.
Across 57 payments — averaging $70.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Medtronic$1K
- Dexcom, Inc.$150
- Corcept Therapeutics$86
- Mannkind Corporation$64
- Tandem Diabetes Care, Inc.$43
- plus $138 from 5 others
What the payments were for
- Consulting fees$2,13053%
- Travel & lodging$78420%
- Food & beverage$1,04726%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $2,427 |
| Medtronic | 12 | $1,095 |
| Dexcom, Inc. | 10 | $150 |
| Corcept Therapeutics | 3 | $86 |
| Mannkind Corporation | 2 | $64 |
| Tandem Diabetes Care, Inc. | 3 | $43 |
| Boehringer Ingelheim | 2 | $37 |
| Lilly USA, LLC | 1 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Sequel Med Tech, LLC | 1 | $23 |
| Nevro Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$2,130
- MINIMED 780G$715
How this compares
$4,003 in reported general payments places this provider in the 80th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 362 | $379,775 |
| MounjaroTirzepatide | 192 | $204,681 |
| JardianceEmpagliflozin | 123 | $119,514 |
| ForteoTeriparatide | 21 | $97,936 |
| TrulicityDulaglutide | 84 | $88,643 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $38,227 |
| Victoza 3-PakLiraglutide | 27 | $21,194 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $21,006 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 46 | $19,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 149 | $18,843 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $17,240 |
| Humalog Kwikpen U-100Insulin Lispro | 75 | $17,020 |
| Novolog FlexpenInsulin Aspart | 66 | $16,974 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $16,566 |
| FarxigaDapagliflozin Propanediol | 19 | $13,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $32 | $396,686314 claims |
| Novo NordiskOzempic | $2,427 | $379,775362 claims |
| Boehringer IngelheimJardiance | $37 | $119,514123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Baldwin
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.